Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein

Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein

Despite current vaccines and therapeutics targeting SARS-CoV-2, the causative agent of the COVID-19 pandemic, cases remain high causing a burden on health care systems. Spike-protein mediated membrane fusion of SARS-CoV-2 is a critical step in viral entry. Herein, we describe entry inhibitors identi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kristin V. Lyles, Shannon Stone, Priti Singh, Lila D. Patterson, Janhavi Natekar, Heather Pathak, Rohit K. Varshnaya, Amany Elsharkawy, Dongning Liu, Shubham Bansal, Oluwafoyinsola O. Faniyi, Sijia Tang, Xiaoxiao Yang, Nagaraju Mulpuri, Donald Hamelberg, Congbao Kang, Binghe Wang, Mukesh Kumar, Ming Luo
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Viruses
Subjects:
coronavirus
spike protein
transmembrane domain
antiviral
entry inhibitor
pan-coronavirus
Online Access:https://www.mdpi.com/1999-4915/17/7/989
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4915/17/7/989

Similar Items